Navigation Links
TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials
Date:2/2/2017

JACKSONVILLE, Fla., Feb. 2, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company's multi-epitope T-cell vaccine targeting folate receptor alpha. The manufactured vaccine product will be used to supply an ongoing Phase 2 study of TPIV 200 for the treatment of platinum-sensitive ovarian cancer, as well as a planned Phase 2 study sponsored by the Mayo Clinic for treating triple-negative breast cancer.

"The successful release of our second lot of TPIV 200 represents another important milestone in the progression of our product pipeline and technologies," said Dr. Glynn Wilson, Chairman and CEO of TapImmune. "Improvements to the manufacturing process include a process change to improve scalability and a formulation change to improve the physical appearance and consistency of the final vialed product. The end result is a superior formulation that is more amenable to large scale manufacturing and commercialization."

Continue Reading
 (PRNewsFoto/TapImmune, Inc.)
(PRNewsFoto/TapImmune, Inc.)...

"Our first TPIV 200 lot was manufactured in early 2016 to fully supply a TapImmune-sponsored Phase 2 trial evaluating the vaccine for the treatment of triple-negative breast cancer as well as a Phase 2 trial evaluating the vaccine in combination with a checkpoint inhibitor for platinum-resistant ovarian cancer, both of which are currently enrolling patients," said Dr. John Bonfiglio, President and COO of TapImmune. "The current, larger clinical batch of TPIV 200 will fully supply the first TapImmune-sponsored Phase 2 trial in platinum-sensitive ovarian cancer, for which a number of clinical sites are currently being screened and initiated. The batch will also supply a planned Mayo Clinic-sponsored Phase 2 trial for triple-negative breast cancer, which is fully funded by a grant from the Department of Defense."

About TapImmune, Inc.
TapImmune, Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at www.tapimmune.com for more details.

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-completes-scale-up-and-gmp-manufacturing-of-tpiv-200-vaccine-to-supply-additional-phase-2-clinical-trials-300401060.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
2. International team completes systematic, genomic study of cervical cancer
3. HITLAB Completes GCP Audit for FDA Smart Device & App Compliance
4. SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays
5. BBI Completes $9 Million Series A Financing
6. Genomics Firm Nabsys Completes Financial Restructuring and Reinstates Technical Leadership Team
7. 3-D Printing and Additive Manufacturing preview issue publishing Fall 2013
8. Nanosensors could aid drug manufacturing
9. Training the future biomanufacturing workforce
10. New technique controls dimensions of gold nanorods while manufacturing on a large scale
11. Manufacturing a new gut to treat GI diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... May 21, 2019 , ... ... biotech companies, turned 20 today, and to celebrate launched a new startup package, ... foundational tools they need – pre-product – to attract talent and investors. , ...
(Date:5/16/2019)... ... May 16, 2019 , ... In a FDA-contracted Standard Coordinating Body ... 18-19 of this year, Asymmetrex founder and director James L. Sherley, M.D., ... therapeutic adult tissue stem cells. Many of the gathered participants dismissed this idea. ...
(Date:5/14/2019)... ... May 13, 2019 , ... NRD, LLC ... in Boston on May 15-16, 2019, the largest medical technology event in the ... engineering, and embedded systems product organizations. , They will be displaying their latest ...
Breaking Biology News(10 mins):
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers are the magic bullet ... products rely on these ingredients to create stable quality food that can withstand ... shift triggers food formulators to seek out alternatives for starches, gums and chemical ...
(Date:5/14/2019)... LA JOLLA, Calif. (PRWEB) , ... May 14, 2019 , ... ... announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet. ... SneakPeek Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The ...
(Date:5/7/2019)... , ... May 06, 2019 , ... ... resource for the growing number of repositories being asked to store cellular products ... to the team of contributors who are world leaders, who have shared their ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the world leader ... Response vision test, a new full field electroretinography (ffERG) protocol designed to ... million Americans will have glaucoma, with black Americans having the highest prevalence rate. ...
Breaking Biology Technology: